sponsored by


Endsleigh offer competitive
Life Insurance policies

Calendar

«« Jun 2007 »»
S M T W T F S
         
1
2
3
4
5
6
7
8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

Search Box

LinkBlog

OCD: Dr. Jeffrey Schwartz' Four Steps

52 Proven Stress Reducers

Webcast: Why are we happy? Why aren't we happy?

Insomnia: Predisposition, Precipitation, Perpetuation

  More

Contact

Mailing List

RSS Feeds








Translation

Disclaimer

All content within Anxiety Insights is provided for general information only, and should not be treated as a substitute for the medical advice of your doctor or other health care professional.

Anxiety Insights is not responsible or liable for any diagnosis made by a reader based on the content of this website.

Anxiety Insights is not liable for the contents of any external internet sites listed, nor does it endorse any commercial product or service mentioned or advised on any of the sites.

Always consult your doctor if you are in any way concerned about your health.

recommended links

Depression is Real's Down & Up Show
      Weekly audio-casts from the
      Depression Is Real Coalition


No Longer Lonely.com

Hit Counter

Total: 711,751
since: 14 May 2006

Admin console

Log-In

My Blog    My Profile

Leave Message

Add as neighbors






Blogion.com

Blog Flux Directory



Blogarama - The Blogs Directory

blog search directory

BlogTagstic - Blog Directory

Find Blogs in the Blog Directory



LS Blogs

Top Health Sites





Health Blogs - Blog Top Sites

Bloggapedia - Find It!

Abstract: Eszopiclon (Lunesta™) Co-Administered With Fluoxetine (Prozac®) in MDD patients with insomnia

« H E » email
posted Monday, 12 June 2006

Bio Psychiatry 2006 June; 59(11):1052-1060

Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder

Fava M, McCall WV, Andrew Krystal A, Wessel T, Rubens R, Caron J, Amato D, Roth T.

Depression Clinical and Research Program, Massachusetts General Hospital, Boston

Background: Insomnia and major depressive disorder (MDD) can coexist. This study evaluated the effect of adding eszopiclone to fluoxetine.

Methods: Patients who met DSM-IV criteria for both MDD and insomnia (n = 545) received morning fluoxetine and were randomized to nightly eszopiclone 3 mg (ESZ+FLX) or placebo (PBO+FLX) for 8 weeks. Subjective sleep and daytime function were assessed weekly. Depression was assessed with the 17-item Hamilton Rating Scale for Depression (HAM-D-17) and the Clinical Global Impression Improvement (CGI-I) and Severity items (CGI-S).

Results: Patients in the ESZ+FLX group had significantly decreased sleep latency, wake time after sleep onset (WASO), increased total sleep time (TST), sleep quality, and depth of sleep at all double-blind time points (all p < .05). Eszopiclone co-therapy also resulted in: significantly greater changes in HAM-D-17 scores at Week 4 (p = .01) with progressive improvement at Week 8 (p = .002); significantly improved CGI-I and CGI-S scores at all time points beyond Week 1 (p < .05); and significantly more responders (59% vs. 48%; p = .009) and remitters (42% vs. 33%; p = .03) at Week 8. Treatment was well tolerated, with similar adverse event and dropout rates.

Conclusions: In this study, eszopiclone/fluoxetine co-therapy was relatively well tolerated and associated with rapid, substantial, and sustained sleep improvement, a faster onset of antidepressant response on the basis of CGI, and a greater magnitude of the antidepressant effect.


(Text has been reformatted for clarity; Ed.)

tags: antidepressant  fluoxetine    major depressive disorder  eszopiclone  prozac  lunesta  

links: digg this    del.icio.us    technorati    reddit